UroGen Pharma
URGN
189 hedge funds and large institutions have $1.56B invested in UroGen Pharma in 2026 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 61 increasing their positions, 54 reducing their positions, and 21 closing their positions.
90% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 21
87% more capital invested
Capital invested by funds: $835M → $1.56B (+$725M)
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
49% more call options, than puts
Call options by funds: $9.8M | Put options by funds: $6.59M
13% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 54
9% more funds holding
Funds holding: 173 → 189 (+16)
8.32% less ownership
Funds ownership: 95.4% → 87.07% (-8.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$41.3M |
| 2 |
SG Americas Securities
New York
|
+$10.7M |
| 3 |
BlackRock
New York
|
+$9.64M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$9.46M |
| 5 |
Goldman Sachs
New York
|
+$6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$47M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
-$30.6M |
| 3 |
JGC
J. Goldman & Co
New York
|
-$19.7M |
| 4 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$7.29M |
| 5 |
Millennium Management
New York
|
-$7.16M |
URGN Hedge Fund Activity: Q2 2026 in Review
189 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q2 2026, worth a combined $1.56B — up 87% from $835M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new URGN positions and 21 closed out — a net gain of 19 holders — while 61 added to existing stakes and 54 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $41.3M. The largest seller was Toronto Dominion Bank, exiting entirely with an estimated $47M sold.
- 189 institutional investors held UroGen Pharma (URGN) as of Q2 2026, up from 173 in Q1 2026.
- Funds reported $1.56B of UroGen Pharma stock for Q2 2026, up 87% quarter-over-quarter.
- 40 funds opened new UroGen Pharma positions in Q2 2026 and 21 closed out, a net change of +19 holders.
- The largest UroGen Pharma buyer in Q2 2026 was Point72 Asset Management, an estimated $41.3M added.
- The largest UroGen Pharma seller in Q2 2026 was Toronto Dominion Bank, an estimated $47M sold.
Based on aggregated 13F filings for Q2 2026.